Oman Pharmaceuticals & Healthcare Report Q1 2015 - New Report Available

The Omani government is placing an increasing emphasis on the healthcare sector , demonstrated by a large increase in funding for the 2015 national budget . M uch of this investment is allocated to building state-of-the-art healthcare infrastructure in an attempt to promote the medical tourism industry. We highlight continuing commercial opportunities in the Omani pharmaceutical market for multinational drugmakers due to the high penetration of patented medicines, lack of local competition and the development of the private healthcare sector.

Headline Expenditure Projections

* Pharmaceuticals: OMR187mn (USD487mn) in 2013 to OMR200mn (USD518mn) in 2014; 6.6% in local currency and US dollar terms. Forecast broadly in line with Q414.
* Healthcare: OMR831mn (USD2.16bn) in 2013 to OMR891mn (USD2.31bn) in 2014; +7.2% in local currency and US dollar terms. Forecast unchanged from Q414.

Full Report Details at
- http://www.fastmr.com/prod/938432_oman_pharmaceuticals_healthcare_report_q1_2015.aspx?afid=301

Risk/Reward Index

Oman has limited longer-term commercial potential due to its small population and the fact that the government is responsible for the bulk of healthcare costs, which will increase the need for cost containment in the coming years. In Q115, Oman's Pharmaceutical Risk/Reward Index (RRI) scores 49.3 out of 100, which has seen the country maintain its position in 10th place in the Middle East and Africa matrix out of 31 countries.

Key Trends And Developments

* The Burjeel Medical Centre was inaugurated in Muscat in October 2014, offering speciality treatment services including internal and family medicine, paediatrics, obstetrics and gynaecology, ophthalmology, general surgery, dental medicine, orthopaedics, cardiology, ENT and dermatology.
* A visiting Indian business delegation of hospitals, healthcare institutes and pharmaceutical companies visited Muscat in September 2014 with the view to expanding into Oman's healthcare sector.
* In September 2014, it was announced that the Ministry of Health in Oman will support private sector hospitals to upgrade...

The Oman Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Oman Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Omani pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Oman to test other views - a key input for successful budgeting and strategic business planning in the Omani pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Peru Pharmaceuticals & Healthcare Report Q1 2015
- Lebanon Pharmaceuticals & Healthcare Report Q1 2015
- Turkey Pharmaceuticals & Healthcare Report Q1 2015
- India Pharmaceuticals & Healthcare Report Q1 2015
- Slovenia Pharmaceuticals & Healthcare Report Q1 2015